Results 21 to 30 of about 1,589,553 (217)
Contribution of congenital disorders to under-5 mortality
No Abstract.
Malherbe, H L +3 more
openaire +4 more sources
Impact of COVID-19 on mortality under 5 years old
This paper investigated impact of COVID-19 on mortality under 5 years old. The mortality effects were calculated with two CDC datasets such as the dataset from 2015 to 2020 and the provisional dataset from 2020 to 2022. The result shows that there is no effect of COVID-19 on mortality under 5 years old.
openaire +2 more sources
ABSTRACT Background Children with sickle cell anemia (SCA) in low‐income settings are at risk of severe malnutrition, but optimal nutritional management has not been established. We evaluated an intensified ready‐to‐use therapeutic food (RUTF) regimen in children with persistent severe malnutrition after initial treatment and assessed whether early ...
Safiya Gambo +9 more
wiley +1 more source
Identifying New Age Patterns of Under-5 Mortality Using the Under-5 Mortality Database
This study brings new insights into the global diversity of the age pattern of under-five mortality. The novelty of our results relies on the newly-compiled Under-Five Mortality Database (U5MD) providing mortality information by detailed age groups, including daily, weekly, and monthly breakdowns.
Verhulst, Andrea +13 more
openaire +2 more sources
Estimation of Under-5 Child Mortality Rates in 52 Low-migration Countries [PDF]
Reduction of the under-5 mortality rate is a target of the Sustainable Development Goals. Therefore, this study aimed to estimate under-5 child mortality rates in 52 low-migration countries using population data. The study utilized population data from the US Census Bureau from 1990 to 2015.
Nirmal Sapkota +3 more
openaire +3 more sources
Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine +17 more
wiley +1 more source
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani +7 more
wiley +1 more source
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk +10 more
wiley +1 more source
A Pseudo-likelihood Approach to Under-5 Mortality Estimation
Accurate and precise estimates of the under-5 mortality rate (U5MR) are an important health summary for countries. However, full survival curves allow us to better understand the pattern of mortality in children under five. Modern demographic methods for estimating a full mortality schedule for children have been developed for countries with good vital
Okonek, Taylor +2 more
openaire +2 more sources
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source

